Office: 210-567-8355
Email: lamf@uthscsa.edu

Variability in pharmacologic response to a drug can be partially related to interindividual differences in pharmacokinetics, which can be modulated by an individual's metabolic capacity and concomitant therapy. Development and availability of different in vitro systems over the years have allowed for identification of major cytochrome P-450 isoenzymes and assessment of enzyme inhibition potentials. My primary research interest is on the pharmacodynamic and pharmacokinetic consequences of cytochrome P-450 isoenzymes-mediated drug metabolism. In vivo probes of different isoenzymes are used to investigate the intrinsic and extrinsic variants affecting metabolic capacity, and to investigate the therapeutic utility of metabolic profiling. These probes also allow an opportunity to further address possible genetic and environmental determinants of drug responsiveness among different ethnic groups.

Selected Publications

Friedberg SJ, Lam YWF, Blum JJ, Gregerman RL. Insulin absorption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus. Metabolism 2006; 55:614-19.

Johnson BA, Javors MA, Lam YWF, Wells LT, Tiouririne M, Roache JD, Ait-Daoud N, Lawson K. Kinetic and cardiovascular comparison of sustained-release and immediate-release isradipine among healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:15-20.

Lam YWF, Javors M, Ait-Daoud N, Roach J, Johnson BA. Relative bioavailability of ondansetron solution versus expemporaneous gelatin capsule formulation containing crushed tablets. Pharmacotherapy 2004; 24:477-81.

Lam YWF, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274-82, 2003.

Shirley KL, Hon YY, Penzak SR, Lam YWF, Spratlin V, Jann MW. Correlation of cytochrome P450 (CYP)1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 28:961-966, 2003.

Lam Y.W.F,, Gaedigk A, Ereshefsky L, Alfaro C, Simpson J. CYP2D6 inhibition by SSRIs: Analysis of achievable plasma concentrations and the effect of ultra-rapid metabolism at CYP2D6. Pharmacotherapy 22:1001-6, 2002.

Alfaro CL, Lam YWF, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacology 19:155-163, 1999.

Lam, Y.W.F,, Jann, M.W., Chang, W.H., Yu, H.S., Lin, S.K., Chen, H. and Davis, C.M. Intra- and inter-ethnic variability in reduced haloperidol to haloperidol ratio. J. Clin Pharmacol 35:128-136, 1995.

Lam Y.W.F., Chang WH, Jann MW, Chen H. Variabilities in haloperidol interconversion and the reduced haloperidol / haloperidol ratio. Neuropsychopharmacology 7:33-39, 1992.